Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its launch in 2018.

“With the series A now raised, Korro will be expanding the senior leadership team which includes a key focus on recruitment of a CEO to support the company long term in partnership with our experienced team of existing leaders, board and SAB,” Bermingham told BioCentury. ...